<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065905</url>
  </required_header>
  <id_info>
    <org_study_id>MSPB_TB</org_study_id>
    <nct_id>NCT05065905</nct_id>
  </id_info>
  <brief_title>Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis</brief_title>
  <acronym>MSPB_TB</acronym>
  <official_title>A I//II Phase Study of the Efficacy and Safety of Interferon-Gamma by Subcutaneous Injection in the Complex Treatment of Patients Infected With HIV and Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SPP Pharmaclon Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North-Western State Medical University named after I.I.Mechnikov</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SPP Pharmaclon Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety and efficacy of interferon-gamma by&#xD;
      subcutaneous injection in complex treatment of patients with co-infection of HIV and&#xD;
      pulmonary tuberculosis and to determine the rational of its use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study will evaluate safety and efficacy of the investigational medical product (IMP) -&#xD;
      interferon-gamma - in participants with HIV-infection and pulmonary tuberculosis.&#xD;
&#xD;
      Interferon-gamma (immune interferon) is an important anti-inflammatory cytokine produced by&#xD;
      NK-cells, CD4 Th1 cells and CD8 cytotoxic supressor cells. Interferon-gamma blocks viral&#xD;
      replication, viral proteins synthesis and assembly of mature viral particles. Causes&#xD;
      cytotoxic effects on the cells infected by intracellular pathogens. Possess a bright&#xD;
      immunomoduling action. Thus, the use of interferon-gamma is patogenetically rational in&#xD;
      patients co-infected with tuberculosis and HIV.&#xD;
&#xD;
      The aim of interferon-gamma use is to achieve a viral replication control, support CD4 level&#xD;
      and help abacillation process. In this randomised, controlled safety and efficacy study&#xD;
      interferon gamma will be administered in a daily dose of 500,000 IU daily or every other day.&#xD;
&#xD;
      The treatment regimen in this study will also include a basic antituberculosis therapy.&#xD;
&#xD;
      The available clinical data do not suggest a risk for serious adverse events (SAEs) from the&#xD;
      IMP used in chosen doses.&#xD;
&#xD;
      The study will screen HIV-infected participants 18-50 years old with pulmonary tuberculosis.&#xD;
      Participants who provide informed consent and meet study entry criteria will be randomised&#xD;
      into 1 of 3 parallel treatment groups. The study will last 30 days, during which participants&#xD;
      will receive IMP in various regimens according to the group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2006</start_date>
  <completion_date type="Actual">April 6, 2006</completion_date>
  <primary_completion_date type="Actual">March 29, 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum culture</measure>
    <time_frame>Week 4</time_frame>
    <description>Precentage of participants with negative sputum culture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average hemoglobin level</measure>
    <time_frame>Screening, Week 8</time_frame>
    <description>Level of hemoglobin (g/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leucocytes level</measure>
    <time_frame>Screening, Week 4</time_frame>
    <description>Number of leukocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD3</measure>
    <time_frame>Screening, Week 4</time_frame>
    <description>CD3 cells level in absolute numbers and percents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4</measure>
    <time_frame>Screening, Week 4</time_frame>
    <description>CD4 cells level in absolute numbers and percents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8</measure>
    <time_frame>Screening, Week 4</time_frame>
    <description>CD8 cells level in absolute numbers and percents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4/CD8</measure>
    <time_frame>Screening, Week 4</time_frame>
    <description>Immunoregulatory index value</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>HIV Coinfection</condition>
  <condition>Aids/Hiv Problem</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Lentivirus Infections</condition>
  <condition>RNA Virus Infections</condition>
  <arm_group>
    <arm_group_label>Interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU alternated with Interal® (interferon alpha) 3,000,000 IU every other day&#xD;
Interventions:&#xD;
Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU given with Interal® (interferon alpha) 3,000,000 IU every day&#xD;
Interventions:&#xD;
Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All participants receive only basic antimicrobial treatment&#xD;
Interventions:&#xD;
Drug: Antituberculosis complex therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-Gamma</intervention_name>
    <description>received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein</description>
    <arm_group_label>Interferon</arm_group_label>
    <arm_group_label>Interferon daily</arm_group_label>
    <other_name>Ingaron</other_name>
    <other_name>Interferon gamma human recombinant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must sign the form of informed consent and agree to follow the protocol&#xD;
             requirements&#xD;
&#xD;
          -  Women willing to participate in the study must protect against possible pregnancy&#xD;
             during all the study long&#xD;
&#xD;
          -  Age 18-50 years&#xD;
&#xD;
          -  Pulmonary tuberculosis&#xD;
&#xD;
          -  HIV/AIDS&#xD;
&#xD;
          -  Indication for in-patient standard antituberculosis treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigational research agents received within 30 days before the screening and&#xD;
             participation in other clinical trials&#xD;
&#xD;
          -  Immunosuppressive medications received within 6 months before the screening&#xD;
&#xD;
          -  Current drug abuse for more than 3 years&#xD;
&#xD;
          -  Contraindications to interferons of standard antimicrobial therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Shmelev, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>SPP Pharmaclon Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint-Petersburg State Medical Academy n.a. I.I.Mechnikov of Ministry of Health</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Saint-Petersburg</state>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Tuberculosis Hospital #2 of Saint-Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Saint-Petersburg</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interferon gamma, IFN-g, HIV infection, tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>RNA Virus Infections</mesh_term>
    <mesh_term>Lentivirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

